SAN DIEGO, March 29, 2021 – Fortis Therapeutics, Inc., an immuno-oncology biotech developing FOR46, a novel antibody drug conjugate (ADC) against CD46, today announced the close of a $40 million Series A financing. Participating in this financing are existing investors, Avalon Ventures, Bregua Corporation, Lilly Asia Ventures, Osage University Partners, and Vivo Capital, as well as new investors, the Myeloma Investment Fund, the venture philanthropy fund of the Multiple Myeloma Research Founda...
In addition, Dr. Eric J. Small was appointed head of Fortis' scientific advisory board SAN DIEGO, September 27, 2016 -- Fortis Therapeutics, Inc., a new immuno-oncology biotech, today announced the close of an $18 million Series A financing. The investment was led by Avalon Ventures and was joined by Bregua Corporation, Lilly Asia Ventures, Osage University Partners, and Vivo Capital. The company was founded on technology from Bin Liu, Ph.D., a professor in the Department of Anesthesia at UC...
SAN DIEGO, November 6, 2018 — Fortis Therapeutics, Inc., an immuno-oncology biotech developing a novel antibody-drug conjugate (ADC) against CD46, today announced the U.S. Food and Drug Administration (FDA) has cleared two investigational new drug (IND) applications for the company’s lead candidate, FOR46, for the treatment of metastatic castration-resistant prostate cancer and late-stage multiple myeloma. The Phase 1 trial of FOR46 in metastatic castration-resistant prostate cancer is plann...